HSTECH Biotech Index Adds DIAGENS-B , Removes HUTCHMED in Quarterly ReviewAASTOCKS News·Aug 21 at 05:26 AMHCM+0.53%00013+0.25%
REG - Hutchmed China Ltd - Announcement pursuant to AIM Rule 17 Schedule 2(g)London Stock Exchange·Aug 18 at 04:00 AMHCM+0.53%00013+0.25%
CICC Raises HUTCHMED TP to HKD26 on Bright Prospects for Overseas Filing of SavolitinibAASTOCKS News·Aug 18 at 03:06 AMHCM+0.53%00013+0.25%
HUTCHMED shares are trading higher after the company announced high-level results from the SAFFRON Phase III trial.benzinga_article·Aug 17 at 07:35 AMHCM+0.53%00013+0.25%
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO® | HCM Stock NewsStockTitan·Aug 16 at 11:00 AMHCM+0.53%00013+0.25%
Huatai Securities Sticks to Their Buy Rating for HUTCHMED (China) (HCM)Tip Ranks·Aug 1 at 12:05 AMHCM+0.53%00013+0.25%
HUTCHMED 1H26 Net Profit USD15.928M, Down 96.5% YoYAASTOCKS News·Jul 30 at 08:41 PMHCM+0.53%00013+0.25%
HUTCHMED (China): Oncology sales surged over 40% in China, global launches expanded, and cash reserves remained strongQuartr·Jul 30 at 06:34 AMHCM+0.53%00013+0.25%
HUTCHMED H1 FY26 net income drops to USD 15.9 million; revenue rises 0.22% to USD 278.3 millionPUBT·Jul 30 at 06:10 AMHCM+0.53%00013+0.25%
STOCKS | Hutchmed (China) Says ORPATHYS Approved in China for MET-Amplified GC/GEJ CancerCoinLive·Jul 2 at 05:33 AM00013+0.25%HCM+0.53%
HUTCHMED to Announce 2026 Half-Year Financial Results | HCM Stock NewsStockTitan·Jun 29 at 07:30 PM00013+0.25%HCM+0.53%
